Mitoxantrone is an anthraquinone antineoplastic agent demonstrating significant clinical activity in metastatic breast cancer, acute leukemias, and non-Hodgkin's lymphoma.
Mitoxantrone is an anthraquinone antineoplastic agent with significant activity in various cancers, including those refractory to anthracyclines.
Mitoxantrone is an anthraquinone antineoplastic agent with structural similarities to doxorubicin. It has a mechanism of action similar to the anthracyclines. Its primary elimination route is hepatic metabolism (only seven percent renal excretion) and it has a terminal half-life of approximately 40 hours. Mitoxantrone has significant activity in the treatment of metastatic breast cancer, acute leukemias, and non-Hodgkin's lymphoma. Some activity is reported in head and neck cancer, Hodgkin's, myeloma, bladder cancer, prostate cancer, non-small-cell lung cancer, and liver cancer. There is a suggestion of incomplete cross-resistance between mitoxantrone and the anthracyclines in certain neoplasms. Some activity is reported with mitoxantrone in patients refractory to the anthracyclines in breast cancer, acute leukemias, and non-Hodgkin's lymphomas. The usual doses used in solid tumors and in lymphomas are mitoxantrone 12-14 mg/m2 iv q3-4wk and in leukemias is mitoxantrone 12 mg/m2/d X 5 d iv for initial induction.
Therese I. Poirier (Sat,) conducted a review in Metastatic breast cancer, acute leukemias, and non-Hodgkin's lymphoma. Mitoxantrone was evaluated. Mitoxantrone is an anthraquinone antineoplastic agent demonstrating significant clinical activity in metastatic breast cancer, acute leukemias, and non-Hodgkin's lymphoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: